Krystal Biotech, Inc. (KRYS) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
Analysis Summary
Trailing-twelve-month margins: gross margin 93.3%, operating margin 44.9%, net margin 54.8%.
Balance sheet quality for KRYS: current ratio of 10.0, net cash position of $818.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $188.9M represents 92% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $336.46 |
| Market Cap | $9.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 39.88 |
| Price / Book | 7.17 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 93.34% |
| Operating Margin | 44.93% |
| Net Margin | 54.82% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 8.32 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | $9.9B | 39.88 | 7.17 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| PCVX | Vaxcyte, Inc. | $8.5B | 3.10 | -37.6% | |
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | ||
| PTGX | Protagonist Therapeutics, Inc. | $9.2B | 8.71 | -21.2% | |
| PTCT | PTC Therapeutics, Inc. | $5.6B | 21.7% | ||
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| CRSP | CRISPR Therapeutics AG | $5.0B | 2.86 |
Price Performance
| 1 month | +1.01% |
| 3 months | -3.41% |
| Year-to-date | +36.36% |
| 1 year | +118.23% |
| 3 years | +183.68% |
52-Week Range
| 52-week High | $382.54 |
| 52-week Low | $153.20 |
| Avg Volume (90d) | 360K |
Related companies: ACLX · ALKS · ARWR · CRSP · MTSR · PCVX · PTCT
Explore sector: Healthcare · Biotechnology
More sections of KRYS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks